Agios to Present at the RBC Capital Markets Global Healthcare Conference on May 16, 2023
CAMBRIDGE, Mass., April 25, 2023 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular...
Pharmaceutical
Achilles Therapeutics Announces Grant of US Patent Covering the Treatment of Patients with an Immunotherapy Targeting Neoantigens Based on Tumor HLA Status
- Patent broadly covers technology to select neoantigens that are presented by HLA molecules determined to be present in a...
Atea Pharmaceuticals Announces U.S. FDA Fast Track Designation Granted to Bemnifosbuvir, an Investigational Oral Antiviral, for the Treatment of COVID-19
BOSTON, April 25, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the...
Reviva Pharmaceuticals to Host Key Opinion Leader Event on Brilaroxazine (RP5063) in Phase 3 Clinical Trials for Schizophrenia
Virtual event on Tuesday, May 2, 2023 at 11:00am ET will feature key opinion leader (KOL) Larry Ereshefsky, PharmD, BCPP,...
Invivyd Announces the FDA Has Cleared Its IND Application for VYD222, a Monoclonal Antibody Candidate for Prevention of COVID-19, and Provides Phase 1 VYD222 Clinical Trial Update
On track for initial readouts in Q2 2023 from ongoing Phase 1 VYD222 clinical trial being conducted in Australia, with...
Morphic Reports Positive Topline Results of the EMERALD-1 UC Main Cohort; Orally Administered MORF-057 Achieves Primary Endpoint and Demonstrates Clinically Meaningful Improvements Across Secondary and Exploratory Measures
-MORF-057 demonstrates statistically significant reduction of 6.4 points (p=0.002) from baseline at Week 12 in the Robarts Histopathology Index (RHI)...
Assertio Provides Educational Grant for New Lennox-Gastaut Syndrome (LGS) Foundation Treatments Kits
SYMPAZAN (clobazam) oral CIV film from Assertio is used for the adjunctive treatment of seizures associated with LGS in patients...
TOMI Environmental Solutions Expands National and Global Presence with the Addition of Four New Partners
FREDERICK, Md., April 24, 2023 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global company specializing in...
binx health and Mark Cuban Cost Plus Drug Company Team Up to Make Healthcare More Accessible and Affordable
Companies join forces to offer at-home access to affordable testing and prescription medications for millions of AmericansBOSTON, April 24, 2023...
Tarsus Appoints Jeff Farrow as Chief Financial Officer and Chief Strategy Officer
IRVINE, Calif., April 24, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet...
LIXTE Biotechnology Reports First Spanish Site Activated to Begin Accrual of Patients for a Phase 1b/2 Clinical Trial of LIXTE’s Lead Anti-Cancer Compound, LB-100, Added to Doxorubicin as First-Line Treatment of Advanced Soft Tissue Sarcoma
First clinical trial seeking to determine if the potentiation of cytotoxic chemotherapy by LB-100 occurs in cancer patients as has...
Panbela to Host First Quarter 2023 Earnings Conference Call on May 4, 2023
MINNEAPOLIS, April 24, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the...
Pharma Two B to Present Additional Positive Results from P2B001 Phase 3 Trial at 2023 American Academy of Neurology Annual Meeting
Results showed P2B001, a once-daily fixed-dose combination of low dose pramipexole and low dose rasagiline, showed comparable efficacy to marketed...
AB Science announces the implementation of a new strategy and the launch of a capital increase
PRESS RELEASE FOCUS OF THE DEVELOPMENT STRATEGY ON AMYOTROPHIC LATERAL SCLEROSIS WITH THE MASITINIB PLATFORM AND ON THE SECOND MICROTUBULE...
Xenon Pharmaceuticals to Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference
BURNABY, British Columbia, April 21, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that...
Vallon Pharmaceuticals Completes Merger with GRI Bio, Inc.
Combined company will operate as GRI Bio, Inc. and advance innovative pipeline of Natural Killer T (“NKT”) modulating therapies for...
Lexicon To Present Results From LX9211 Phase 2 Trial In Postherpetic Neuralgia At The 2023 American Academy Of Neurology (AAN) Annual Meeting And The British Pain Society (BPS) 56th Annual Scientific Meeting 2023
Data accepted as AAN Late-Breaking AbstractTHE WOODLANDS Texas, April 21, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today...
Disc Medicine to Participate in H.C. Wainwright BioConnect Investor Conference
WATERTOWN, Mass., April 21, 2023 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery,...
Clearmind Medicine Expanding IP Portfolio with New US Patent Application for Treatment of Depression
The application is for a novel psychedelic-based combination, of Clearmind's MEAI and SciSparc's Cannamide™ Tel Aviv, Israel / Vancouver, Canada,...
SciSparc and Clearmind Collaboration Strengthens IP Portfolio with Patent Application in the U.S. for Treatment of Depression
The application refers to a novel psychedelic-based combination of Clearmind's MEAI and SciSparc's Cannamide™ TEL AVIV, Israel, April 21, 2023 (GLOBE NEWSWIRE)...